TB: What is big pharma doing?
This article was originally published in Scrip
The Access to Medicine Index has analyzed where big pharma companies are focusing their R&D efforts to tackle TB. The Index found that big pharma is focusing mainly on developing new vaccines and drugs, and that its efforts are concentrated on drug-resistant strains of TB.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.